Header Logo

Connection

Paul Ruff to Antineoplastic Agents, Immunological

Back to Details
This is a "connection" page, showing publications Paul Ruff has written about Antineoplastic Agents, Immunological.
Paul Ruff
Connection Strength
0,060
Antineoplastic Agents, Immunological
  1. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One. 2024; 19(11):e0309778.
    View in: PubMed
    Score: 0,060
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.